Journal
ANNALES D ENDOCRINOLOGIE
Volume 80, Issue 2, Pages 128-133Publisher
MASSON EDITEUR
DOI: 10.1016/j.ando.2018.11.002
Keywords
Extrinsic factors; Insulin-producing cells; Pluripotent stem cells; Reprogramming; Stem cells
Categories
Funding
- National Natural Science Foundation of China [81760150]
- Science and Technology Program of Jiangxi Province [20151BAB205019, 20144BAB2050007]
Ask authors/readers for more resources
In the modern world, type-2 diabetes mellitus has become a leading public healthcare problem, due to major risks of morbidity and mortality. Prevalence has increased significantly in recent decades. Treatment involves oral hypoglycemic agents or insulin replacement therapy. Development is ongoing for cell-based diabetes therapies using stem cells with the potential to differentiate into insulin-producing cells (IPCs): embryonic stem cells (ESCs), mesenchymal stem cells (MSCs), induced pluripotent stem cells (iPSCs), and stem cells from adult pancreas, liver, central nervous system, bone marrow and adipose tissue. Successful induction of iPSCs, however, depends on the quantity and quality of available stem cells and the development of adapted protocols determining the environment of extrinsic factors and involvement of small molecules. Validating such new cell therapies must be founded on this experimental rationale. (C) 2019 L'Auteur(s). Publie par Elsevier Masson SAS.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available